POMDOCTOR (POM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed May 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the POM SEC filings page.
POMDOCTOR LIMITED (POM) reported $57.2M in revenue for fiscal year 2025, up 21.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expanded, but overhead costs accelerated, leaving the business dependent on financing amid severe balance-sheet pressure.
Revenue grew21.9% in FY2025 while SG&A rose138.5% , so additional sales were overwhelmed by overhead expansion. Operating margin fell22.1 percentage points as operating cash flow reached-$21.2M , linking the reported deterioration to cash pressure rather than an accounting-only loss.
Gross margin was
Liabilities were
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of POMDOCTOR LIMITED's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
POMDOCTOR LIMITED held $1.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $21.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and POMDOCTOR LIMITED scores 4/100 among other emerging companies.
Not available for POMDOCTOR LIMITED, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
POMDOCTOR LIMITED spent $1.8M on research and development in fiscal year 2025, which was 2.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and POMDOCTOR LIMITED scores 16/100 among other emerging companies.
POMDOCTOR LIMITED reported revenue of $57.2M in fiscal year 2025, against $46.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and POMDOCTOR LIMITED scores 61/100 among other emerging companies.
POMDOCTOR LIMITED's operations used $21.2M of cash in fiscal year 2025, against $2.2M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and POMDOCTOR LIMITED scores 10/100 among other emerging companies.
POMDOCTOR LIMITED's cash, cash equivalents and investments came to $1.4M at the end of fiscal year 2025, against $80.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and POMDOCTOR LIMITED scores 5/100 among other emerging companies.
POMDOCTOR LIMITED scores -33.38, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $354.1M against total assets of $15.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
POMDOCTOR LIMITED passes 0 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, neither operating efficiency signal passes.
POMDOCTOR LIMITED reported a net loss of $18.7M while operations used $21.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
POMDOCTOR LIMITED reported an operating loss of $17.0M against $563K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
POMDOCTOR LIMITED generated $57.2M in revenue in fiscal year 2025. This represents an increase of 21.9% from the prior year.
POMDOCTOR LIMITED's EBITDA was -$16.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
POMDOCTOR LIMITED reported a net loss of $18.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
POMDOCTOR LIMITED recorded an outflow of $21.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
POMDOCTOR LIMITED held $1.4M in cash against $11.7M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
POMDOCTOR LIMITED's gross margin was 13.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the prior year.
POMDOCTOR LIMITED's operating margin was -29.7% in fiscal year 2025, reflecting core business profitability. This is down 22.1 percentage points from the prior year.
POMDOCTOR LIMITED's net profit margin was -32.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
POMDOCTOR LIMITED invested $1.8M in research and development in fiscal year 2025. This represents an increase of 347.3% from the prior year.
POMDOCTOR LIMITED invested $144K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2684.7% from the prior year.
Not reported for fiscal year 2025.
POM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Revenue | $57.2M+21.9% | $46.9M+9.3% | $42.9M |
| Cost of Revenue | $49.7M+23.1% | $40.4M+7.8% | $37.5M |
| Gross Profit | $7.5M+14.4% | $6.5M+19.8% | $5.5M |
| R&D Expenses | $1.8M+347.3% | $411K-13.4% | $475K |
| SG&A Expenses | $22.3M+138.5% | $9.3M+18.6% | $7.9M |
| Operating Income | -$17.0Mn/m | -$3.5Mn/m | -$3.1M |
| EBITDA | -$16.9Mn/m | -$3.5Mn/m | -$3.1M |
| Interest Expense | $563K+13.2% | $498K+17.7% | $423K |
| Income Tax | $54 | N/A | N/A |
| Net Income | -$18.7Mn/m | -$5.1Mn/m | -$5.2M |
| EPS (Basic) | -$3.14 | -$3.11n/m | -$3.25 |
| EPS (Diluted) | -$3.14 | -$3.11n/m | -$3.25 |
| Diluted Shares (Avg) | 10M | 6M0.0% | 6M |
POM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Total Assets | $15.4M+142.9% | $6.3M | N/A |
| Current Assets | $15.0M+192.2% | $5.1M | N/A |
| Cash & Equivalents | $1.4M+30.7% | $1.0M+10.8% | $946K |
| Short-Term Investments | $0n/m | $0n/m | $0 |
| Inventory | $1.2M-5.7% | $1.3M | N/A |
| Accounts Receivable | $2.6M+129.8% | $1.1M | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0 |
| Total Liabilities | $80.3M+1108.7% | $6.6M | N/A |
| Current Liabilities | $31.2M | N/A | N/A |
| Non-Current Liabilities | $53.0M | N/A | N/A |
| Long-Term Debt | $11.7M | N/A | N/A |
| Total Equity | -$64.9Mn/m | -$310K | N/A |
| Retained Earnings | -$354.1Mn/m | -$310.1Mn/m | -$298.6M |
Not reported in any period shown, so not listed: Goodwill.
POM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Operating Cash Flow | -$21.2Mn/m | -$2.2Mn/m | -$6.5M |
| Depreciation & Amortization | $21K+15.9% | $18K+16.7% | $16K |
| Stock-Based Compensation | $2.3M | N/A | N/A |
| Capital Expenditures | $144K+2684.7% | $5K-67.2% | $16K |
| Free Cash Flow | -$21.4Mn/m | -$2.2Mn/m | -$6.5M |
| Investing Cash Flow | -$230Kn/m | -$5Kn/m | -$16K |
| Financing Cash Flow | $22.0M+844.2% | $2.3M-66.9% | $7.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
POM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.
Note: Shareholder equity is negative (-$64.9M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.48), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where POMDOCTOR LIMITED Ranks
Frequently Asked Questions
What is POMDOCTOR LIMITED's annual revenue?
POMDOCTOR LIMITED (POM) reported $57.2M in total revenue for fiscal year 2025. This represents a 21.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is POMDOCTOR LIMITED's revenue growing?
POMDOCTOR LIMITED (POM) revenue grew by 21.9% year-over-year, from $46.9M to $57.2M in fiscal year 2025.
Is POMDOCTOR LIMITED profitable?
No, POMDOCTOR LIMITED (POM) reported a net loss of $18.7M in fiscal year 2025, with a net profit margin of -32.7%.
What is POMDOCTOR LIMITED's EBITDA?
POMDOCTOR LIMITED (POM) had EBITDA of -$16.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does POMDOCTOR LIMITED have?
As of fiscal year 2025, POMDOCTOR LIMITED (POM) had $1.4M in cash and equivalents against $11.7M in long-term debt.
What is POMDOCTOR LIMITED's gross margin?
POMDOCTOR LIMITED (POM) had a gross margin of 13.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is POMDOCTOR LIMITED's operating margin?
POMDOCTOR LIMITED (POM) had an operating margin of -29.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is POMDOCTOR LIMITED's net profit margin?
POMDOCTOR LIMITED (POM) had a net profit margin of -32.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is POMDOCTOR LIMITED's free cash flow?
POMDOCTOR LIMITED (POM) recorded an outflow of $21.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is POMDOCTOR LIMITED's operating cash flow?
POMDOCTOR LIMITED (POM) recorded an outflow of $21.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are POMDOCTOR LIMITED's total assets?
POMDOCTOR LIMITED (POM) had $15.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are POMDOCTOR LIMITED's capital expenditures?
POMDOCTOR LIMITED (POM) invested $144K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does POMDOCTOR LIMITED spend on research and development?
POMDOCTOR LIMITED (POM) invested $1.8M in research and development during fiscal year 2025.
What is POMDOCTOR LIMITED's current ratio?
POMDOCTOR LIMITED (POM) had a current ratio of 0.48 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is POMDOCTOR LIMITED's return on assets (ROA)?
POMDOCTOR LIMITED (POM) had a return on assets of -121.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is POMDOCTOR LIMITED's P/E ratio?
POMDOCTOR LIMITED (POM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.9M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is POMDOCTOR LIMITED's price-to-sales ratio?
POMDOCTOR LIMITED (POM) trades at 0.1x sales, its market capitalization divided by $57.2M revenue, FY2025. The market capitalization is $3.9M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does POMDOCTOR LIMITED's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, POMDOCTOR LIMITED (POM) held $1.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $21.2M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is POMDOCTOR LIMITED's debt-to-equity ratio negative or not reported?
POMDOCTOR LIMITED (POM) has negative shareholder equity of -$64.9M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is POMDOCTOR LIMITED's Altman Z-Score?
POMDOCTOR LIMITED (POM) has an Altman Z-Score of -33.38, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is POMDOCTOR LIMITED's Piotroski F-Score?
POMDOCTOR LIMITED (POM) has a Piotroski F-Score of 0 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are POMDOCTOR LIMITED's earnings high quality?
POMDOCTOR LIMITED (POM) reported a net loss of $18.7M while operations used $21.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can POMDOCTOR LIMITED cover its interest payments?
POMDOCTOR LIMITED (POM) reported an operating loss of $17.0M against $563K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is POMDOCTOR LIMITED?
POMDOCTOR LIMITED (POM) scores 19 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For POMDOCTOR LIMITED it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.